PT  - JOURNAL ARTICLE
AU  - Martinez-Resendez, Michel F.
AU  - Castilleja-Leal, Fernando
AU  - Torres-Quintanilla, Alejandro
AU  - Rojas-Martinez, Augusto
AU  - Garcia-Rivas, Gerardo
AU  - Ortiz-Lopez, Rocio
AU  - Trevino, Victor
AU  - Lara-Medrano, Reynaldo
AU  - Villanueva-Lozano, Hiram
AU  - Ramirez-Elizondo, Teresa
AU  - Sanchez-Nava, Victor M.
AU  - Moreno-Hoyos, Francisco
AU  - Martinez-Thomae, Alfonso
AU  - Hernández-Torre, Martin
AU  - Diaz-Olachea, Carlos
AU  - Cardona-Huerta, Servando
AU  - de la Rosa-Pacheco, Sylvia
AU  - Diaz-Garza, Carlos
AU  - Reynoso-Lobo, Paola
AU  - Marroquin-Escamilla, Alma R.
AU  - Herrera-Gamboa, Jessica G.
AU  - Alvarado-Monroy, Fatima M.
AU  - Aguayo-Millan, Claudia D.
AU  - Villegas-Macedo, Francisco F.
AU  - Flores-Osorio, Jesus Efrain
AU  - Davila-Gonzalez, Daniel
AU  - Diaz-Sanchez, María Eugenia
AU  - Torre-Amione, Guillermo
TI  - Initial experience in Mexico with convalescent plasma in COVID-19 patients with severe respiratory failure, a retrospective case series
AID  - 10.1101/2020.07.14.20144469
DP  - 2020 Jan 01
TA  - medRxiv
PG  - 2020.07.14.20144469
4099  - http://medrxiv.org/content/early/2020/07/20/2020.07.14.20144469.short
4100  - http://medrxiv.org/content/early/2020/07/20/2020.07.14.20144469.full
AB  - Introduction Hospital mortality due to COVID-19 in Mexico is high (32%) and as of today, effective treatment options are limited. More effective treatments that shorten hospital stay and reduce mortality are needed. Initial reports for the use of convalescent plasma (CP) therapy for COVID-19 appear promising. We describe a case series of eight patients with impending respiratory failure, who underwent CP therapy.Methods Six male and two female (ages 31 to 79) patients that were admitted to the intensive-care unit for severe COVID-19 were transfused with two doses of CP (250 mL per dose, anti-SARS-CoV-2 IgG titers > 1:100). Donors were six SARS-CoV-2 infected males who remained asymptomatic for > 7 days and were negative for two nasopharyngeal RT-PCR tests. Clinical characteristics, inflammatory and cellular injury markers, chest X-ray findings and viral loads were analyzed before and after CP administration. Viral load association to disease severity was further analyzed on a separate cohort of asymptomatic vs hospitalized patients with COVID-19.Results Eight patients with respiratory failure were successfully discharged with a median length of stay of 22.5 (IQR 18.25-29.00). After CP therapy, we observed a reduction of C-reactive protein (CRP) (median, 22.80 mg/dL vs. 1.63 mg/dL), and of procalcitonin (median, 0.27 ng/mL vs. 0.13 ng/mL). High-Sensitivity Cardiac Troponin I (hs-cTnI), Brain Natriuretic Peptide (BNP) and Lactate Dehydrogenase (LDH) were lower, and a mild reduction of pulmonary infiltrates by chest X-ray was observed. Lastly, a reduction of viral load was after CP therapy was found. (log, median [IQR], 1.2 [0.70-2.20] vs. 0.25 [0.00-1.78]). We observed no adverse effects.Conclusions CP could potentially be an effective therapeutic option for patients with severe COVID-19. Clinical benefit needs to be studied further through randomized controlled trials.Competing Interest StatementThe authors have declared no competing interest.Clinical TrialA retrospective analysis of first patients treated with convalescent plasma before official trial registration. NCT04333355 Funding StatementThis work was partially supported by Fundacion TecSalud. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:This study was approved by the Clinical Research Ethics Committee of the School of Medicine at Tecnologico de Monterrey (P000353-COVID-19 TecSalud-CEIC-CR001). Written informed consent was obtained from all patients. All patients received CP treatment under compassionate use due to impending respiratory failure after case review by the hospital bioethics committee.All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesThe dataset supporting results presented here has been deposited in the Harvard Dataverse repository. https://doi.org/10.7910/DVN/QJPC2X COVID-19Coronavirus Disease 2019BNPBrain Natriuretic PeptideCPConvalescent Plasmahs-cTnIHigh-sensitivity Cardiac Troponin IIL-1Interleukin-1IL-6Interleukin-6JAKJanus KinaseLDHLactate DehydrogenaseNAbsNeutralizing antibodiesRT-PCRReverse transcription polymerase chain reactionSARS-CoV-2Severe acute respiratory syndrome coronavirus 2